CD19 and juvenile dermatomyositis: CAR T-cell therapy targeting B cells (CD19 or BCMA) has great potential to clinically improve and possibly reset the B-cell immune system and subsequently allow discontinuation of all immunomodulatory medication, with limited reports including in JDM.